- Home
- AUST vs MRKR Comparison
AUST vs MRKR Comparison
Compare AUST & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | MRKR |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 23.0M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AUST | MRKR |
|---|---|---|
| Price | $1.48 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 124.6K | 120.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $644.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $0.81 |
| 52 Week High | $3.92 | $4.07 |
Technical Indicators
Market Signals| Indicator | AUST | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 52.64 |
| Support Level | $1.44 | $1.33 |
| Resistance Level | $1.66 | $1.43 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 67.74 | 72.73 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.